219551-85-6

Basic information

• Product Name: 3-benzyl-5,7-dihydroxy-4-methyl-2H-chromen-2-one
• Synonyms: 3-benzyl-5,7-dihydroxy-4-methyl-2H-chromen-2-one
• CAS NO: 219551-85-6
• Molecular Formula: C₁₇H₁₄O₄
• Molecular Weight: 282.29066
• Mol File: 219551-85-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-benzyl-5,7-dihydroxy-4-methyl-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-5,7-dihydroxy-4-methyl-2H-chromen-2-one(219551-85-6)
• EPA Substance Registry System: 3-benzyl-5,7-dihydroxy-4-methyl-2H-chromen-2-one(219551-85-6)

Safety Data

• Hazardous Substances Data: 219551-85-6(Hazardous Substances Data)

Upstream product

• 108-73-6 3,5-dihydroxyphenol 
• 620-79-1 Ethyl 2-benzylacetoacetate 
• 6099-90-7 1,3,5-Trihydroxybenzene dihydrate 

Downstream Products

• 1005322-70-2 3-benzyl-5-hydroxy-4,8-dimethyl-8,9-dihydro-2H,10H-pyrano[2,3-f]chromene-2,10-dione 
• 1005322-71-3 3-benzyl-5-hydroxy-4,8-dimethyl-7,8-dihydro-2H,6H-pyrano[3,2-g]chromene-2,6-dione 
• 1604838-44-9 9-benzyl-5-hydroxy-2,2-dimethyl-10-methyl-8-oxo-2H,8H-pyrano[2,3-f]chromen-6-carbaldehyde 
• 1604838-53-0 C₂₄H₁₉NO₆ 
• 1604838-35-8 C₁₈H₁₄O₅ 

Relevant articles and documents

1-Nicotinoylbenzotriazole: A Convenient Tool for Site-Selective Protection of 5,7-Dihydroxycoumarins

1-Nicotinoylbenzotriazole (NicBt) was uncovered as an efficient protecting agent for the site-selective acylation of resorcinol-type phenolic groups with almost equal reactivity. The use of NicBt allows selective protection of the 7-OH group in 5,7-dihydr

Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)

This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also re

Method for the prevention and treatment of stunned myocardium

A method for the prevention and treatment of stunning of the heart subsequent to ischemia-reperfusion is described. The method comprises administering a therapeutically effective amount of a phospholamban inhibitor to a patient. Phospholamban inhibitors r